Your Messages Inbox
Your Article Summary
See Latest ArticlesDevelopment of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease
Expert Opinion in Pharmacotherapy, 06/19/09
Henley DB et al. - Semagacestat seems to be well tolerated, with most adverse events related to its actions on inhibition of peripheral Notch cleavage. Thus far, clinical efficacy has not been detectable because of the short duration of the current trials. Phase III trials with 21 months of active treatment are currently underway.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
The Unintended Consequences of Clinical Trials Regulations
PLoS Medicine, 12/04/09
Characterization of Baseline Methicillin-Resistant Staphylococcus aureus Isolates Recovered from Phase IV Clinical Trial for Linezolid
Journal of Clinical Microbiology, 12/03/09
Bayer Starts Phase III Trial with Florbetaben
BayNews International, 12/01/09
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists
Amgen, 12/04/09
Bayer Team wins the “Deutscher Zukunftspreis” awarded by the German President
BayNews International, 12/03/09
GSK Update: GSKs Arepanrix H1N1 pandemic vaccine prequalified by the World Health Organization
GlaxoSmithKline, 12/02/09
Article Search
Sponsor